Bayer and Dr. Reddy's sign marketing and distribution agreement for second brand of Vericiguat in India
Vericiguat works on a pathway not currently targeted by existing heart failure treatments
Vericiguat works on a pathway not currently targeted by existing heart failure treatments
A game changing solution for the pharmaceutical industry
The approval marks a significant milestone for the American pharmaceutical company in the field of UC
Combination will create a Canadian Health Champion spanning generic, biosimilar and branded pharmaceuticals
The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
The company had earlier announced about the approval received from the MHRA for Liraglutide
Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus
Centhaquine is a resuscitative agent presently indicated for the treatment of hypovolemic shock by DGCI
Ukrainian marketing approvals for paclitaxel, oxaliplatin and irinotecan mark a significant milestone in the company’s global expansion strategy
Subscribe To Our Newsletter & Stay Updated